Eltrombopag: Phase III data
The 2-part, international Phase III PETIT2 (TRA115450) trial in 93 patients aged 1-17 years with previously treated chronic ITP showed that eltrombopag met the primary endpoint of a greater proportion of patients achieving a platelet count of >=50 Gi/L for 6 weeks out of weeks 5-12 in the double-blind portion of the trial vs. placebo (39.7% vs. 3.4%, p<0.001). The trial consisted of a double-blind portion in which patients received eltrombopag or placebo for 13 weeks followed by an open-label portion in which all patients received eltrombopag for 24 weeks. Data were presented at the European Hematology Association meeting in Milan. This year, GlaxoSmithKline plans to submit regulatory applications for eltrombopag to treat pediatric chronic ITP. ...